Researchers at the University of Bergen in Norway have identified a potential new cause for pediatric cancer, which may enable earlier detection of the disease in young children. The study, published in Frontiers in Immunology, suggests children with pediatric cancer produce autoantibodies that target proteins needed for normal DNA repair.
The presence of these autoantibodies was noted even years before diagnosis, indicating a possible predictive marker for cancer risk. Pediatric cancer, though rare, includes types such as leukemia, lymphoma, brain, spinal cord, and bone tumors, differing from adult cancers, which more commonly affect organs like the lungs, breast, and colon.
Understanding Autoantibodies
Autoantibodies differ from typical antibodies that protect the body, as they mistakenly attack healthy tissues. This malfunction can lead to autoimmune diseases such as type 1 diabetes, lupus, and multiple sclerosis. The exact cause of autoantibody production remains unclear, but triggers may include infections, environmental toxins, or genetic factors.
Study Findings
The research involved testing tumor and blood samples from 175 individuals with sarcoma or acute lymphoblastic leukemia. These were part of the NoSarC Norwegian Sarcoma Study, Norwegian Childhood Cancer Biobank, and Oslo University Hospital Cancer Research Biobank. Samples were compared with healthy anonymized participants from the Bergen Growth Study.
Results showed significantly higher levels of IgG class antibodies, which interact with genes involved in DNA repair, in children aged two to 19 with cancer. Ola Myklebost, study author and professor of molecular oncology, noted that these autoantibodies might impair DNA repair activity, increasing mutation rates and cancer risks.
Outside expert Dr. Yvonne Saenger highlighted the importance of understanding immune response differences for immunotherapy applications, suggesting further research into whether autoantibodies influence cellular processes.
Implications of the Findings
Myklebost proposed an intriguing hypothesis on cancer development, potentially extending beyond childhood to young adults and occasionally adults. Screening for these autoantibodies could eventually help assess cancer risk and lead to therapies to block or eradicate antibody-producing cells.
Anastassia Serguienko, a senior researcher involved in the study, emphasized the need to focus future research on the mechanisms of these penetrating autoantibodies, considering their potential role in various human diseases.